[ATTACH=full]47997[/ATTACH]

[MEDIA=youtube]_VPxl41xRp4[/MEDIA]

Chapters:

0:00—Introduction to GLP-1 Drugs

08:48—Obesity as a Major Health Concern

11:52—Diabetes: The Original Indication for GLP-1

15:26—Cardiovascular Implications of GLP-1

20:16—Kidney Health and GLP-1 Mechanisms

24:02—Exploring GLP-1 Effects on Mental Health

29:27—Challenges and Side Effects of GLP-1 Treatments

42:48—Q&A Session Introduction

49:33—Conclusion and Future Directions in GLP-1

An overview of glucagon-like peptide 1 (GLP-1) drugs, their applications, and their impact on the present and future of healthcare, the economy, and society.

This session provides a comprehensive overview of GLP-1 agonists and their current and future impact on healthcare.

GLP-1 agonists are a class of medication that mainly helps manage blood sugar (glucose) levels in people with Type 2 diabetes and also have effects in weight management.

Other than lowering blood sugar levels and reducing weight, GLP-1 agonists may also:

• Lower blood pressure.

• Improve lipid disorders.

• Improve fatty liver disease.

• Reduce the risk of heart and kidney diseases.

• Delay the progression of diabetes-related nephropathy.

As the market for GLP-1 drugs experiences tremendous growth, understanding their wide applications, potential risks, and effects on the economy and society is essential for anyone in the pharmaceutical and healthcare industries. 

What will you learn? 

• The history of GLP-1 receptor antagonists and their significant contribution to the treatment of diabetes.

• The potential of GLP-1 drugs to treat obesity and other major health disorders.

• How GLP-1 drugs function in different organ systems.

• The projected economic impact of GLP-1 drugs.

Who may this interest? 

• Pharmaceutical and biotech companies

• Healthcare professionals and clinicians

• Pharmaceutical researchers and scientists

• Regulatory and compliance specialists

Presented by Dr. Gaetano Morelli, MD, Chief Medical Officer, Altasciences: Dr. Morelli is a member of the Collège des Médecins du Québec, a Fellow of the Royal College of Physicians of Canada, certified in Internal Medicine and Gastroenterology, and a Fellow of the American College of Gastroenterology. Dr. Morelli has over 30 years of medical-clinical experience and 25 years of experience in clinical research.  He joined Altasciences in 2017 as a medical advisor/consultant for complex studies. 

Altasciences is an integrated drug development solution company, offering pharmaceutical and biotechnology companies of all sizes a proven, flexible approach to their preclinical and clinical study needs. From lead candidate selection to proof of concept, we offer one-stop integrated formulation, preclinical and clinical manufacturing and analytical services. For over 25 years, Altasciences has been integrating into clients’ projects to help support educated, faster, and more complete early drug development decisions. Altasciences’ full-service solutions include preclinical safety testing, clinical pharmacology, bioanalysis, program management, medical writing, biostatistics, and data management, all of which can be tailored to specific sponsor requirements.